U.S. Online Retail and Ecommerce Stock News

NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Assessing Nuvalent (NUVL) Valuation As A High P/B And DCF Gap Shape Expectations

Nuvalent (NUVL) has drawn investor attention as a clinical stage cancer drug developer with no current revenue, a reported net loss of US$381.435 million, and a share price of US$103.59. See our latest analysis for Nuvalent. Recent trading has been mixed, with a 2.67% 1 day share price return and an 11.41% 90 day share price return. The 1 year total shareholder return of 20.90% and 3 year total shareholder return of about 3.6x indicate that longer term momentum has been much stronger than...
NasdaqCM:ABTC
NasdaqCM:ABTCSoftware

Is American Bitcoin (ABTC) Pricing Reflect Recent 28% Slide And DCF Value Estimate

If you are trying to figure out whether American Bitcoin's share price really lines up with its underlying value, you are in the right place. This article is built to help you make sense of what the current price might be implying. The stock most recently closed at US$1.31, after a 13.2% decline over the last 7 days and a 28.4% decline over the last 30 days, with year to date returns at a 26.4% decline. These moves have put American Bitcoin on the radar for investors who track more volatile...
NasdaqGS:QS
NasdaqGS:QSAuto Components

Is QuantumScape (QS) Share Price Out Of Sync With Its Long Term Potential?

If you are wondering whether QuantumScape's current share price lines up with its long term promise, this article will walk you through how the numbers stack up. The stock closed at US$8.47 recently, with a 4.3% decline over 7 days, a 20.2% decline over 30 days, a 23.4% decline year to date, a 71.5% gain over the past year, a 3.2% gain over 3 years, and an 84.5% decline over 5 years. Recent attention on QuantumScape has been driven less by short term events like earnings and more by its...
NasdaqGS:PAGP
NasdaqGS:PAGPOil and Gas

Plains GP Holdings PAGP Quarterly Loss Deepens And Tests Bullish Recovery Narrative

Plains GP Holdings (PAGP) closed FY 2025 with fourth quarter revenue of US$10.6b and basic EPS of a US$0.20 loss, while trailing twelve month revenue came in at US$44.3b with basic EPS of a US$0.62 loss. The company reported quarterly revenue of US$12.4b in Q4 2024 and US$10.6b in Q4 2025, with basic EPS moving from a US$0.06 loss to a US$0.20 loss over the same period. This has set up a results season where investors are weighing volume stability against pressure on earnings. Given the mix...
NYSE:RDW
NYSE:RDWAerospace & Defense

Redwire (RDW) Valuation Check After SHIELD Contract Access To US$151b Missile Defense Opportunity

SHIELD contract opens a new channel of potential work Redwire (RDW) recently secured a position on the Missile Defense Agency's SHIELD indefinite delivery indefinite quantity contract, a multi company vehicle with a US$151b ceiling and no guaranteed revenue. See our latest analysis for Redwire. Redwire's latest SHIELD contract news comes after a sharp 62.72% 90 day share price return, even though the 1 year total shareholder return is a 52.03% decline and the 3 year total shareholder return...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Is Enphase Energy (ENPH) Price Jump Justified After Solar Sector Sentiment Shift?

If you are looking at Enphase Energy and wondering whether the current share price reflects its true worth, this article will help you connect the recent moves in the stock to what the fundamentals might be saying. The shares last closed at US$49.80, with returns of 34.7% over the past week, 41.4% over the past month, and 47.6% year to date, set against a 21.6% decline over the past year and much larger falls over the last 3 and 5 years. Recent news flow around Enphase Energy has focused on...
NYSE:MSCI
NYSE:MSCICapital Markets

MSCI (MSCI) Valuation Check As Earnings Growth Meets Softer Q4 And Higher Buybacks And Dividend

Why MSCI’s latest earnings, buybacks and dividend move matter MSCI (MSCI) is back in the spotlight after its fourth quarter and full year 2025 results, updated share repurchase activity, and a higher cash dividend, all of which directly affect shareholder returns. For the fourth quarter, MSCI reported sales of US$822.53 million, compared with US$743.51 million a year earlier. Net income was US$284.67 million versus US$305.52 million, with diluted earnings per share from continuing operations...
NYSE:PFE
NYSE:PFEPharmaceuticals

Assessing Pfizer (PFE) Valuation After New PF-3944 Obesity Trial Data And Market Reentry

Pfizer (PFE) is back in the obesity spotlight after reporting Phase 2b VESPER-3 data for its monthly GLP-1 injection, PF-3944, showing up to 12.3% placebo adjusted weight loss at week 28. See our latest analysis for Pfizer. The PF-3944 data lands after a busy spell for Pfizer, including better than expected Q4 2025 adjusted earnings, reaffirmed 2026 revenue guidance, a fresh Priority Review for hemophilia drug HYMPAVZI, and ongoing cost and pricing pressures such as TrumpRx agreements. The...
NYSE:KKR
NYSE:KKRCapital Markets

KKR Expands Fee Engine With Sports Ownership And Data Center Push

KKR (NYSE:KKR) has agreed to acquire Arctos Partners, moving directly into investments in professional sports franchises. The firm plans to create a new unit called KKR Solutions, with Arctos forming a key part of this expanded platform. Separately, KKR has agreed to acquire a majority stake in ST Telemedia Global Data Centres, one of Asia's largest data center operators. The ST Telemedia Global Data Centres deal is described as KKR's largest infrastructure investment in Asia Pacific. For...
NasdaqCM:STEX
NasdaqCM:STEXMedical Equipment

Is Streamex (STEX) Using Academic Star Power To Strengthen Its Capital Markets Narrative?

Streamex Corp. recently appointed Anthony Marciano, Clinical Professor of Finance at NYU Stern and former senior Wall Street banker, as an independent director to its Board, adding deep expertise in corporate finance, mergers and acquisitions, and capital markets. Marciano’s combination of academic influence and high-level investment banking experience may reinforce Streamex’s governance credentials as it expands its tokenization and capital markets initiatives. Next, we will examine how...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Assessing Structure Therapeutics (GPCR) Valuation As Oral Obesity Drug GSBR-1290 Advances In Phase 2

Why GSBR-1290’s phase 2 progress matters for Structure Therapeutics (GPCR) Structure Therapeutics (GPCR) is back in focus as its oral obesity candidate GSBR-1290 advances through phase 2 trials. This is a key clinical stage that can materially influence sentiment around the company’s pipeline and valuation. See our latest analysis for Structure Therapeutics. At a share price of US$74.92, Structure Therapeutics has had a mixed short term pattern, with a 1 day share price return of 2.34% but a...
NYSE:STE
NYSE:STEMedical Equipment

Is STERIS (STE) Fairly Priced After Recent Sector Attention And Premium P/E Ratio

If you are wondering whether STERIS is priced fairly at around US$252 per share, you are not alone; many investors are asking whether the current tag matches the underlying business. The stock has had a mixed run recently, with a 4% decline over the last week, a 1.8% decline over the last month, but returns of 0.8% year to date, 14.1% over 1 year, 34.6% over 3 years and 44.3% over 5 years. Recent news coverage has focused on STERIS as a key player in healthcare equipment and services, which...
NYSE:FUBO
NYSE:FUBOInteractive Media and Services

FuboTV Revenue Beat Sparks Questions On Content Deals And Valuation Gap

FuboTV (NYSE:FUBO) reports Q4 revenue that comes in above its own expectations. The company highlights progress on a planned Hulu Live integration to broaden content access for subscribers. Management addresses an ongoing dispute with NBCUniversal while emphasizing continuity of its service. FuboTV adopts new monetization approaches using Disney's ad platform to refine its advertising business. FuboTV operates in the crowded live TV streaming market, where viewers are trading traditional...
NasdaqGS:HNST
NasdaqGS:HNSTPersonal Products

Assessing Honest Company (HNST) Valuation After Hydrorich Cream Skincare Launch

Hydrorich Cream launch and why Honest Company (HNST) is back on investors’ radars Honest Company (HNST) just expanded its skincare lineup with Hydrorich Cream, a new moisturizer aimed at dry and extra dry skin, and investors are asking what this means for the stock. See our latest analysis for Honest Company. Hydrorich Cream arrives at a time when Honest Company’s short term trading has been choppy, with a 7 day share price return of 7.29% decline and a 30 day share price return of 11.24%...
NasdaqGS:EXPO
NasdaqGS:EXPOProfessional Services

Exponent (EXPO) Is Up 11.0% After Raising Dividend And Guiding For High-Single-Digit 2026 Growth - Has The Bull Case Changed?

Exponent, Inc. recently reported fourth-quarter 2025 results showing year-on-year growth in sales and revenue, modestly higher earnings per share, and full-year 2025 revenue of US$582.01 million alongside a slightly lower annual net income of US$106.01 million. The company paired this earnings beat with guidance for high-single-digit revenue growth in 2026, an increased quarterly dividend to US$0.31 per share, and emphasis on demand tied to artificial intelligence, user research, and risk...
NYSE:FOR
NYSE:FORReal Estate

Is It Too Late To Consider Forestar Group (FOR) After Strong Recent Share Price Gains

Wondering if Forestar Group at around US$29.27 is offering genuine value or if the easy gains are already behind it? This article walks through the key numbers so you can judge the price with more confidence. The stock has delivered returns of 12.5% over 7 days, 6.8% over 30 days, 20.4% year to date, 27.8% over 1 year and a very large 3 year gain. This naturally raises questions about how much of the good news might already be reflected in the share price. Recent price moves are set against...
NasdaqGS:MNST
NasdaqGS:MNSTBeverage

Is Monster Beverage (MNST) Pricing Reflect Its Strong Energy Drink Position?

If you are wondering whether Monster Beverage's current share price really reflects what you are getting for your money, you are not alone. This article is written with that question front and center. The stock last closed at US$82.54, with reported returns of 2.2% over 7 days, 6.7% over 30 days, 8.4% year to date, 77.2% over 1 year and 80.0% over 5 years. This naturally raises questions about how the present price lines up with underlying value. Recent news coverage around Monster Beverage...
NYSE:DOLE
NYSE:DOLEFood

Dole Filing Shift Brings U.S. Style Reporting And Valuation Focus

Dole plc announced it will begin filing using U.S. domestic issuer forms while keeping its foreign private issuer status. The company plans to transition its filings going forward to align more closely with U.S. reporting practices. This change is intended to increase comparability with U.S. public companies and may affect index eligibility. Dole (NYSE:DOLE) is making a reporting shift that could matter if you follow U.S. equities closely. By choosing domestic issuer forms while retaining...
NYSE:M
NYSE:MMultiline Retail

Is Macy’s (M) Accelerated Store Closures Rewriting Its Dividend and Reinvention Playbook?

Macy’s has accelerated its restructuring by closing a major fulfillment center in Owasso, Oklahoma, and moving ahead with most of 14 planned store closures, affecting hundreds of jobs as it streamlines its supply chain and store base. These steps, part of a broader transformation plan, raise fresh questions about how Macy’s will balance reinvestment needs with its ongoing dividend payments to shareholders. We’ll now look at how accelerated store closures and supply-chain changes may reshape...
NYSE:SILA
NYSE:SILAHealth Care REITs

Is Sila Realty Trust (SILA) Pricing Reflect Its Portfolio Focus And DCF Upside Potential

If you are wondering whether Sila Realty Trust is priced fairly or if there is still value on the table, this article will walk through what the current share price might be telling you. The stock last closed at US$25.06, with recent returns of 2.9% over 7 days, 7.5% over 30 days, 6.6% year to date, 5.8% over 1 year and 9.6% over 5 years, which provides some context for how the market has been reacting. Recent news coverage around Sila Realty Trust has focused on its position within the US...
NYSE:AMT
NYSE:AMTSpecialized REITs

American Tower Leadership Shifts And CoreSite Recognition Meet Undervalued Shares

American Tower (NYSE:AMT) appointed Paul Blanchett as Senior Vice President and Chief Accounting Officer, marking a leadership change at the corporate level. CoreSite, an American Tower subsidiary, received industry recognition as Chief Revenue Officer Maile Kaiser was named to the 2026 CRN Channel Chiefs list. The news highlights leadership shifts and partner focused initiatives tied to data center growth and AI enablement within the broader American Tower platform. American Tower, through...
NYSE:RXO
NYSE:RXOTransportation

RXO Resets Credit And Writes Down Goodwill While Leaning On AI

RXO (NYSE:RXO) has arranged a new US$450 million asset based lending facility, replacing prior credit agreements. The company has recorded a goodwill impairment in response to ongoing freight market pressures. RXO is advancing AI driven tools and building a larger late stage sales pipeline to support performance. RXO runs an asset light freight brokerage and logistics business, so prolonged weakness in freight markets directly affects pricing, shipment volumes, and the value of certain...
NYSE:PAGS
NYSE:PAGSDiversified Financial

Is PagSeguro Digital (PAGS) Still Attractive After Its Recent Share Price Rebound?

If you are wondering whether PagSeguro Digital is still attractively priced or if the easy gains are already behind it, looking closely at its valuation metrics can help you frame that question clearly. The share price recently closed at US$10.99, with returns of 6.8% over 30 days, 13.7% year to date, 56.0% over 1 year, 27.5% over 3 years and an 81.3% decline over 5 years. This gives a mixed picture of how the market has treated the stock over different timeframes. Recent news flow around...
NasdaqGS:NVCR
NasdaqGS:NVCRMedical Equipment

Assessing NovoCure (NVCR) Valuation After Prolonged Share Price Weakness In Tumor Treating Fields Story

NovoCure (NVCR) has drawn attention after a prolonged share price slump, with negative returns over the past year and the past 3 months prompting investors to reassess how its current valuation lines up with its oncology device business. See our latest analysis for NovoCure. The recent 7 day share price return of 18.23% decline and 30 day share price return of 29.34% decline add to a year long total shareholder return of 54.43% decline. This points to fading momentum as investors reassess...